Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major…
<!-- Name:DistributionId Value:8782715 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
SPL026
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive…
LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration…
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New…
Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key…